Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Insulin Aspart (Fiasp®)

Brand: Fiasp®
Indication: Treatment of diabetes mellitus in adults
Disease category: Endocrine system
Commissioning responsibility: CCG
PbR excluded: No


Must be commenced by a healthcare professional who is appropriately trained and experienced in the initiation of insulin.
Insulin Aspart (Fiasp®) is recommended for the treatment of diabetes mellitus in adults who are suitable for NovoRapid® and their diabetes cannot be adequately managed with alternative formulary choices and at least one of the following applies:

•where the prescriber believes a faster onset of action would be beneficial to the patient
•where a patient requires ‘tight’ control of blood sugar levels
•where a patient has rapid post meal increase in blood sugar levels


LMMG recommendation: Green (Restricted)
Click here to find the definitions for the colour classifications

Reason for decision:  Suitable for initiation in primary care

Supporting documents:

LMMG New Medicine Recommendation - Insulin Aspart (Fiasp®) (610.0 KiB)

Algorithm For Antihyperglycaemic Therapy In Adults With Type II (Version 1.4) (585.4 KiB)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Green (Restricted)

Green (Restricted)


Green (restricted)

Green (Restricted)